First identified as a powerful vasoconstrictor, endothelin has an extremely diverse set of
actions that influence homeostatic mechanisms throughout the body. Two receptor subtypes …

Endothelin receptor antagonists (ERAs) have been developed to block the effects of
endothelin-1 (ET-1) in a variety of cardiovascular conditions. ET-1 is a powerful …

Endothelin receptor antagonists for pulmonary arterial hypertension - Liu, C - 2021 | Cochrane
Library Skip to Content Cookies Our site uses cookies to improve your experience. You can …

Since its initial characterization in 1988, over 18,236 papers, including 2,485 reviews, have
been published in the endothelin (ET) field. Over this period, several generations of …

Abstract Treatment options for pulmonary arterial hypertension (PAH) have considerably
improved in the past few years. Endothelin (ET)-receptor antagonism has been established …

Lee SH, Rubin LJ (University of California, San Diego, La Jolla, CA, USA). Current treatment
strategies for pulmonary arterial hypertension (Review). J Intern Med 2005; 258: 199–215 …

Pulmonary hypertension can occur as an isolated disease affecting the lung vessels only, in
association with underlying hypoxic lung disorders, or due to chronic thromboembolic …

Endothelin 1 (ET-1), a potent vasoconstrictive substance, was discovered in 1988 by
Yanagisawa and colleagues, and since then, a quarter of a century has passed …

The long-term effects of endothelin receptor antagonists on pulmonary arterial pressure
(PAP) and pulmonary vascular resistance (PVR) in patients with pulmonary arterial …

OBJECTIVE: To assess safety and efficacy of sitaxsentan 50 and 100 mg in patients with
pulmonary arterial hypertension (PAH). BACKGROUND: Sitaxsentan is a highly selective …